Abstract
This chapter discusses the role of chemistry within the pharmaceutical industry [1–3]. Although the focus is upon the industry within the United States, much of the discussion is equally relevant to pharmaceutical companies based in other first-world nations such as Japan and those in Europe. The primary objective of the pharmaceutical industry is the discovery, development, and marketing of safe and efficacious drugs for the treatment of human disease. However, drug companies do not exist as altruistic, charitable organizations. As with other shareholder-owned corporations within a capitalistic society, drug companies must earn profits in order to remain viable. Profits from the enterprise finance the essential research and development that leads to new drugs designed to address unmet medical needs. Thus, there exists a tension between the dual goals of enhancing the quality and duration of human life and that of increasing stockholder equity. Much has been written and spoken in the lay media about the high prices of prescription drugs and the hardships these place upon the elderly and others of limited income. Consequently, some consumer advocate groups support governmental imposition of price controls on ethical pharmaceuticals in the United States, such as those that exist in a number of other countries. However the out-of-pocket dollars spent by patients on prescription drugs must be weighed against the more costly and inherently risky alternatives of surgery and hospitalization, which can often be obviated by drug therapy. Consideration must also be given to the enormous expense associated with the development of new drugs. It typically takes 10 or more years from the inception of a drug in the laboratory to registrational approval and marketing at an overall cost which is now estimated to be in excess of $800 million and increasing, a figure that includes the opportunity costs of failed development campaigns. Only 1 out of 10,000–20,000 compounds prepared as potential drug candidates ever reach clinical testing in humans and the attrition rate of those that do is >80%, a success rate that has been stubbornly difficult to change despite advances in improving candidate quality and significant increases in investment in research and development. The expense of developing a promising drug grows steadily further through the pipeline it progresses; clinical trials can be several orders of magnitude more costly than the preclinical development of a compound. While the sales of drugs that complete clinical trials and reach the shelves of pharmacies can eventually recoup their developmental expenses many times over if successful, many fail to do so and the cost of the drugs that fail is never recovered.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Krogsgaard-Larsen P, Liljefors T, Madsen U (eds) (1996) A textbook of drug design and development, 2nd edn. Harwood Academic, Amsterdam
Spilker B (1989) Multinational drug companies; issues in drug discovery and development. Raven, New York
Wermuth CG (ed) (1996) The practice of medicinal chemistry. Academic, San Diego
Wess G, Urmann M, Sickenberger B (2001) Medicinal chemistry: challenges and opportunities. Angew Chem Int Ed 40:3341–3350
Lipinski CA, Lombardo F, Dominy DW, Feeny PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3–25
Stella VJ, Borchardt RT, Hageman MJ, Oliyai R, Maag H, Tilley JW (eds) (2007) Prodrugs: challenges and rewards, vols. 1–2. Springer, New York
Gauwerky K, Borelli C, Korting HC (2009) Drug Discov Today 14:214–222
Miertus S, Fassina G (eds) (1999) Combinatorial chemistry and technology; principles, methods and applications. Marcel Dekker, New York
Dolle R (2001) Comprehensive survey of combinatorial library synthesis: 2000. J Comb Chem 3:477–518
Anderson NG (2000) Practical process research and development. Academic, New York
Laird T (2010) Organic process research and development 14(4): 942–1045
Rubin AE, Tummala S, Both DA, Wang C, Delaney E (2006) Emerging technologies supporting chemical process R&D and their increasing impact on productivity in the pharmaceutical industry. Chem Rev 106:2794–2810
Farina V, Reeves JT, Senanayake CH, Song JJ (2006) Asymmetric synthesis of active pharmaceutical ingredients. Chem Rev 106:2734–2793
Brands KM, Payack JF, Rosen JD, Nelson TD, Candelario A, Huffman MA, Zhao MM, Li J, Craig B, Song ZJ, Tschaen DM, Hansen K, Devine PN, Pye PJ, Rossen K, Dormer PG, Reamer RA, Welch CJ, Mathre DJ, Tsou NN, McNamara JM, Reider PJ (2003) Efficient synthesis of NK(1) receptor antagonist aprepitant using a crystallization-induced diastereoselective transformation. J Am Chem Soc 125:2129–2135
Hewitt Bradley D, Burk Mark J, Johnson Nicholas B (2000) Improved process for asymmetric hydrogenation. Pharmacia & Upjohn. WO 00/055150, Sep, 21 2000.
Hansen KB, Hsiao Y, Xu F, Rivera N, Clausen A, Kubryk M, Krska S, Rosner T, Simmons B, Balsells J, Ikemoto N, Sun Y, Spindler F, Malan C, Grabowski EJ, Armstrong JD III (2009) Highly efficient asymmetric synthesis of sitagliptin. J Am Chem Soc 131:8798
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media New York
About this chapter
Cite this chapter
Kadow, J.F., Meanwell, N.A., Eastman, K.J., Yeung, KS., Payack, J. (2012). Chemistry in the Pharmaceutical Industry. In: Kent, J. (eds) Handbook of Industrial Chemistry and Biotechnology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-4259-2_11
Download citation
DOI: https://doi.org/10.1007/978-1-4614-4259-2_11
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4614-4258-5
Online ISBN: 978-1-4614-4259-2
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)